The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)

Publications

Nelson BE, Hong A, Okereke I, Markowitz A, Willis M, Muthukumarana PV, Nawgiri R

Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung.

Diagnostic cytopathology 2021 Jul 31;; — 2021 Jul 31

Mahjoubi L, Gazzah A, Marabelle A, Le Roy Ladurie F, Lambotte O, Caramella C, Adam J, Besse B, Soria JC

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990) 2017 11;85;155-157 — 2017 11 — 155-157

Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G

Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.

Lung cancer (Amsterdam, Netherlands) 2016 09;99;162-5 — 2016 09 — 162-5

Sano T, Uhara H, Mikoshiba Y, Kobayashi A, Uchiyama R, Tateishi K, Yamamoto H, Okuyama R

Nivolumab-induced organizing pneumonia in a melanoma patient.

Japanese journal of clinical oncology 2016 Mar;46;270-2 — 2016 Mar — 270-2